About | Free Trial

Last Update

2011-02-08T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Background Information

Employment History

Chief Executive Officer and Co-founder
Synchroneuron Inc

Senior Executive Positions In Development
Eisai Inc.

Senior Executive Positions In Development
SmithKline Beecham Corporation

Affiliations

Treasurer
NTSRI

Scientific Advisory Board Member
Taiwan Liposome Company

Advisor
Critical Path Institute

Scientific Advisory Board
Ricerca Biosciences LLC

Board Member
Calvert Holdings , Inc.

Education



American College of Veterinary Pathologists

DVM

DVM

The Ohio State University

MS

MS

Ohio State University

Web References (149 Total References)


William D. Kerns DVM, MS, ...

www.synchroneuron.com [cached]

William D. Kerns DVM, MS, DACVP Chief Executive Officer and Co-founder

...
Dr. Kerns is a pathologist, pharmacologist, inventor and entrepreneur. He has 30 years of experience in pharmaceutical research and development, having held senior executive positions in development at SmithKlineFrench, SmithKlineBeecham and Eisai for 20 years. He has managed and participated in the successful development and prosecution of more than 200 INDs and 15 NDAs. He has started several companies in the biotech space since 2001.
He is a recognized expert in drug development, safety assessment and mechanisms of drug-induced cardiovascular toxicity. Dr. Kerns has authored or co-authored more than 100 articles and co-edited a book on cardiovascular toxicology. He has been actively involved in numerous organizations and he co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. He completed his medical training in veterinary medicine and graduate work in pharmacology and pathology at The Ohio State University. Dr. Kerns is a board certified Veterinary Pathologist.


William D. Kerns DVM, ...

www.synchroneuron.com [cached]

William D. Kerns DVM, MS Chief Executive Officer


Synchroneuron | Board of Directors

www.synchroneuron.com [cached]

William D Kerns DVM, MS Interim CEO

Dr. Kerns is an entrepreneur and co-founder of Synchroneuron Inc. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of cardiac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists.
Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham (both now part of GlaxoSmithKline), and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment with a focus on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. .
Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA.
Dr. Kerns is also a co-founder and the CEO of Accellient Partners, LLC, a drug development consultancy.


Synchroneuron | Management Team

www.synchroneuron.com [cached]

William D Kerns DVM, MS, DACVP Interim CEO

Dr. Kerns is an entrepreneur and co-founder of Synchroneuron Inc. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of cardiac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists.
Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham, and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment and an expert on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. .
Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA. .
Dr. Kerns is also a co-founder and the CEO of Accellient Partners, LLC, a drug development consultancy in Waltham, MA.


Synchroneuron | Management Team

www.synchroneuron.com [cached]

William D Kerns DVM, MS, DACVP Interim CEO

Dr. Kerns is an entrepreneur and co-founder of Synchroneuron Inc. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of cardiac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists.
Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham, and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment and an expert on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. .
Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA. .
Dr. Kerns is also a co-founder and the CEO of Accellient Partners, LLC, a drug development consultancy in Waltham, MA.

Similar Profiles

Other People with this Name

Other people with the name Kerns

Sandra Kerns
State of West Virginia

Debbie Kerns
BHHS Northwest Real Estate

Silas Kerns
Epoch Universal Inc

M. Kerns
aliya.com

Jack Kerns
Team Sledd

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory